Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benzhydrocodone/paracetamol - KemPharm

Drug Profile

Benzhydrocodone/paracetamol - KemPharm

Alternative Names: Acetaminophen/benzhydrocodone; Acetaminophen/KP-201; AG-APADAZ; Apadaz; APAP/KP-201; Benzhydrocodone and acetaminophen; Benzhydrocodone/acetaminophen; KP-201/acetaminophen; KP-201/APAP; KP201/IR; Paracetamol/benzhydrocodone; Paracetamol/KP-201

Latest Information Update: 14 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KemPharm
  • Class Acetanilides; Antipyretics; Benzoates; Epoxy compounds; Morphinans; Non-opioid analgesics; Opioid analgesics; Opioid peptides; Small molecules
  • Mechanism of Action Opioid receptor agonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Acute pain

Most Recent Events

  • 31 Oct 2019 KemPharm and KVK-Tech intend to launch APADAZ its authorized generic in the US in November 2019
  • 07 Jan 2019 The US FDA approves Supplemental New Drug Application for Benzhydrocodone/paracetamol for two new doses
  • 30 Oct 2018 KemPharm enters into a collaboration and licensing agreement with KVK Tech for the commercialisation of benzhydrocodone/paracetamol in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top